Britain's cost agency not ready to back Gilead hepatitis C drug
LONDON
The National Institute for Health and Care Excellence (NICE) said it was "minded not to recommend" the drug, which is also known as sofosbuvir. The decision poses a hurdle to its widespread adoption in Britain. ...
UK gatekeepers nix hep C drug Sovaldi till Gilead ponies up more evidence
FiercePharma - 3 hours ago
Should the British health service pay for the expensive-yet-effective
hepatitis C treatment Sovaldi? The U.K.'s cost-effectiveness gatekeepers
say they're not convinced. With an $84,000 price tag in the U.S.,
Sovaldi has touched off a vociferous debate about ...
...
"The available evidence shows that sofosbuvir is an effective treatment for chronic hepatitis C in certain patients," Carole Longson, director of NICE's health evaluation center, said in a statement. "However, evidence is lacking for some subgroups of patients with chronic hepatitis C, and there are also substantial uncertainties in the evidence base presented by the manufacturer."
It's an early guidance, with final word expected in October. In the realm of NICE's "not minded to" decisions, it's fairly positive. Chances are that Gilead ($GILD) can sway the outcome with additional evidence and number-crunching. But NICE's evaluation could spur price negotiations; often, the agency presses drugmakers for discounts or other cost-cutting schemes, and successfully. Already, Gilead has priced Sovaldi much lower in the U.K. than in the U.S., at about $57,000.
UK Cost Regulator May Reject Gilead's Sovaldi Treatment
Businessweek - 8 hours ago
The U.K.'s health-cost regulator said it may reject Gilead Sciences
Inc. (GILD:US)'s $60,000 hepatitis C drug Sovaldi, and asked for more
data before deciding whether the British government should pay for the
treatment. Gilead lacks evidence on Sovaldi for ...
No comments:
Post a Comment